Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Erica Gorman

Nurse Practitioner, Family Blue Springs, MO Nurse Practitioner

NPI 1184155236 CMS profile 11203771

600 Ne Adams Dairy Pkwy, Blue Springs, MO 64014

Open in the dashboard

General payments

$14,067

786 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erica Gorman of Blue Springs, MO is reported in the CMS Open Payments database as having received $14,067 across 786 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,332 303
2024 General $5,095 272
2023 General $3,115 176
2022 General $524 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erica Gorman
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Erica Gorman were reported at $5,332. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Erica Gorman Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $524 $141 $44–$430 $149
2023 $3,115 $154 $49–$476 $160
2024 $5,095 $165 $51–$504 $164
2025 $5,332 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $3,014 107 payments
  2. AbbVie, Inc. $1,431 89 payments
  3. Pfizer Inc. $1,172 102 payments
  4. Regeneron Healthcare Solutions, Inc. $952 81 payments
  5. Genzyme Corporation $919 42 payments
  6. GlaxoSmithKline, LLC. $865 48 payments
  7. Amgen Inc. $655 35 payments
  8. CSL Behring $641 36 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $441 29 payments
  10. Pharming Healthcare, Inc. $419 19 payments
  11. Other $3,558 198 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $13,999 785 payments
  2. Education $68 1 payment
Products named General payments · program years 2022–2025
  1. FASENRA $1,664 49 payments
  2. DUPIXENT Immunology $1,262 53 payments
  3. TEZSPIRE Respiratory $1,007 33 payments
  4. BREZTRI $883 12 payments
  5. RINVOQ $737 49 payments
  6. ZAVZPRET $704 69 payments
  7. DUPIXENT Inflammation And Immunology $642 49 payments
  8. NURTEC ODT $608 63 payments
  9. TEZSPIRE Inflammation $596 30 payments
  10. AIRSUPRA $530 11 payments
  11. Other $8,693 529 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

79

Median for Nurse Practitioner: 389

Drug cost

$11,106

Median for Nurse Practitioner: $21,885

Branded share of claims

43%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $9,639
Albuterol Sulfate Hfa Albuterol Sulfate Brand 23 $910
Omeprazole Generic 17 $318
Prednisone Generic 28 $239

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$736 — —
TEZSPIRE
$722 — —
FASENRA
$492 — —
RINVOQ
$399 — —
XOLAIR
$291 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

786 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record